Related Experiment Video
Updated: May 6, 2026

Microscopy Based Methods for the Assessment of Epithelial Cell Migration During In Vitro Wound Healing
Published on: January 2, 2018
Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF
Aymara Fernández Lorente1, Soraida Acosta Brooks, Elia Neninger Vinageras
1Center of Molecular Immunology, Clinical Research Direction, PO Box: 16040, Havana 11600, Cuba. aymaraf@cim.sld.cu.
Background:
The epidermal growth factor receptor (EGFR) signaling system is frequently unbalanced in human malignancies due to increased ligand production, receptor overexpression, receptor mutations, and/or cross-talk with other receptor systems. For this reason, the EGFR is an attractive target for anticancer therapy. The epidermal growth factor also plays an important role in regulating multiple facets of cutaneous wound healing, including inflammation, wound contraction, proliferation, migration, and angiogenesis. In the Center of Molecular Immunology, a cancer vaccine is produced (CIMAvax® EGF) that blocks the binding of EGF to its receptor. This blockade causes a significant inverse association between the anti-EGF antibody titers and EGF concentration. Around 1,500 patients with non-small cell lung cancer have been treated, showing that this vaccine is safe, immunogenic, increases survival and improves quality of life. Taking into account the therapeutic benefits of CIMAvax® EGF vaccination and the role of EGF-EGFR system in the wound healing process, we decided to conduct a retrospective research with the aim of determining the effect to the CIMAvax® EGF vaccine on the wound healing process in patients undergoing surgical treatment.
Methods:
Medical records of 452 vaccinated patients were reviewed and only six patients receiving surgical treatment were identified. Further information about these six patients was obtained from source documents, including medical records and operative reports using an observational list that included different variables. Post-surgical wound healing complications were identified using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTC) version 3.0.
Results:
None of the six patients operated on presented adverse events related to the wound healing, that is to say, no wound dehiscence, wound infection, delayed wound healing, fistula formation, abscess formation or hemorrhage/bleeding associated with surgery during treatment with CIMAvax® EGF occurred.
Conclusions:
These results suggest that the use of CIMAvax® EGF does not produce a deleterious effect in the wound healing process.
Insights
CIMAvax® EGF cancer vaccine did not negatively impact wound healing in surgical patients. This study found no adverse events related to wound healing in patients treated with the epidermal growth factor (EGF) vaccine.
Area of Science:
- Oncology
- Immunology
- Wound Healing Research
Background:
- The epidermal growth factor receptor (EGFR) signaling pathway is dysregulated in many cancers, making it a therapeutic target.
- EGFR also plays a critical role in cutaneous wound healing processes.
- CIMAvax® EGF is a cancer vaccine designed to block EGF-EGFR interaction, demonstrating safety and efficacy in non-small cell lung cancer patients.
Observation:
- A retrospective study reviewed medical records of 452 patients vaccinated with CIMAvax® EGF.
- Six patients who underwent surgical treatment while on CIMAvax® EGF therapy were identified for detailed analysis.
- Wound healing complications were assessed using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTC) version 3.0.
Findings:
- None of the six surgical patients treated with CIMAvax® EGF experienced wound healing complications.
- Specifically, no instances of wound dehiscence, infection, delayed healing, fistula, abscess, or significant bleeding were observed.
Implications:
- The findings suggest that CIMAvax® EGF vaccination does not adversely affect surgical wound healing.
- This indicates a potential for concurrent use of CIMAvax® EGF with surgical interventions without compromising patient recovery.
- Further research could explore the specific mechanisms underlying the lack of negative impact on wound repair.
More Related Videos
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Mitogens and the Cell Cycle
Cytotoxic Edema: Pathophysiology

